Eligen Technology

Novartis initiates second phase-I trial for oral PTH1-34 to treat postmenopausal osteoporosis
Pharmabiz
Sat, 04/17/10 - 12:53 pm
Novartis
Emisphere
Eligen Technology
PTH1-34
osteoporosis